Impact of oral early antiviral therapies for mild–moderate COVID-19 in the outpatient’s setting during Omicron era: a pharmacoeconomic analysis
Abstract Background Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) decreased mortality and hospital admissions in high-risk patients with mild to moderate COVID-19. Nevertheless, there is a lack of data about the pharmacoeconomic impact of these antivirals in the Omicron era. We conducted a pha...
Saved in:
| Main Authors: | Vincenzo Scaglione, Samuele Gardin, Lolita Sasset, Nicolò Presa, Alberto Rossetto, Deris Gianni Boemo, Sofia Silvola, Umberto Restelli, Annamaria Cattelan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | European Journal of Medical Research |
| Online Access: | https://doi.org/10.1186/s40001-024-02154-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-05-01) -
Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis
by: Giacomo Berti, et al.
Published: (2025-04-01) -
Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings
by: M. V. Zhuravleva, et al.
Published: (2022-07-01) -
Fungal Infections in Kidney Transplant Recipients: A Comprehensive Narrative Review
by: Maria Mazzitelli, et al.
Published: (2025-01-01) -
Antiviral effect of Bromelain combined with acetylcysteine against SARS-CoV-2 Omicron variant
by: Erik Vinicius de Sousa Reis, et al.
Published: (2025-04-01)